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Pancreatic cancer (PC) is of the most highly aggressive malignant disease, and currently the
fourth most frequent cause of cancer-related mortality in the United States [1]. It is expected
that approximately 43,920 people are diagnosed with PC and about 37,390 will die of this
disease in 2012 [1]. Despite recent therapeutic advancement, the median survival rate is less
than 6 months, and 5-year survival rate is less than 5%. The high mortality and poor
prognosis are due to extensive metastasis, lack of early symptoms, and lack of reliable early
diagnostic markers [1]. Hence, it is important to understand the molecular mechanism(s)
underlying this devastating disease in order to develop new therapeutic strategies for
improving the therapeutic outcome of patients diagnosed with PC.
Emerging evidence suggests that microRNAs (miRNAs) play a pivotal role in the
development and progression of PC [2]. It is well documented that miRNAs are a family of
the 17–25-nucleotide-long non-coding RNAs that govern the expression of approximately
30% of the protein-coding genes in human genome [2]. The miRNAs repress translation or
degrade the target mRNA through binding to the 3’UTR (3’ untranslated region) of target
mRNA. It is worth mentioning that miRNAs could function as either oncogenes or tumor
suppressor genes, suggesting that the expression of miRNAs could be dependent on tumor
types [2]. Very interestingly, one individual miRNA could regulate more than hundred
mRNA targets, whereas one gene could be controlled by several miRNAs [2].
There is a wealth of literature supporting that deregulation of miRNAs are involved in the
development and progression of human malignancies including PC [2]. It has been reported
that the expression profiles of miRNAs could provide clues to pancreatic tumorigenesis
because miRNA expression profiles could differentiate among normal pancreas, chronic
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tpancreatitis, and PC. For example, Roldo et al. [3] found that up-regulation of miR-103 and
miR-107 as well as down-regulation of miR-155 could be helpful to discriminate pancreatic
tumors from the normal pancreas. We also found that miR-200 was down-regulated in the
compound transgenic mice with activated K-ras and Ink4a/Arf deficiency that quickly
develop pancreatic tumors [4]. Moreover, we identified up-regulation of miR-21, miR-221,
miR-27a, miR-27b and miR-155, and down-regulation of miR-216a, miR-216b, miR-217
and miR-146a expression in tumors derived from this mouse model [5]. In addition, over-
expression of miR-21 has been found to be associated with metastasis [3], and patients with
increased miR-196a-2 have poor survival [6]. Consistent with these results, we also found
that 37 miRNAs were decreased and 54 miRNAs were increased in the plasma of PC
patients [7]. Specifically, miR-21 was up-regulated, whereas let-7 family and miR-146a
were significantly down-regulated in the plasma of PC patients. More importantly, miR-21
expression was associated with worse survival, while let-7 expression was inversely
correlated with survival [7]. These results suggest that unique miRNA signatures could be
useful for the screening of high-risk patients and may serve as biological markers for disease
status.
Multiple studies have demonstrated that miRNAs play pivotal roles in EMT (epithelial-to-
mesenchymal transition) phenotype in PC. The EMT is a fundamental process whereby
epithelial cells undergo conversion into mesenchymal cells. During EMT, cells lose
epithelial characteristics with down-regulation of epithelial markers such as E-cadherin and
γ-catenin, and gain the expression of mesenchymal markers including Vimentin,
fibronectin, Twist, ZEB1, ZEB2, Slag, and Snail. Recently, it has been reported that
miR-200 can directly target mesenchymal markers ZEB1 and ZEB2 in PC cell lines [8, 9].
Consistent with this finding, we also found that miR-200 and let-7 family was down-
regulated in gemcitabine resistant PC cells that have undergone EMT [10]. Very recently,
one study showed that miR-126 plays an essential role in the inhibition of invasive growth
of PC cells through regulation of ADAM9 expression, leading to the induction of epithelial
marker E-cadherin [11]. These published data suggest that miRNAs play critical roles in the
acquisition of EMT.
Accumulating evidence suggests that miRNAs are involved in PC stem cells (CSCs).
Pancreatic CSCs have been identified and isolated from human PC by flow cytometry using
cell surface markers including CD44, CD24, ESA, CD133, and c-Met [12]. Recently, Ji et
al. [13] identified that pancreatic CSCs have lower expression of miR-34, indicating that
miR-34 could be involved in pancreatic CSCs self-renewal. Moreover, miR-34 was reported
to govern pancreatic CSCs self-renewal through modulation of Notch and Bcl-2. Nalls et al.
[14] reported that miR-34a is a critical regulator of pancreatic cancer progression through
regulation of CSC characteristics. Moreover, differentially expressed miRNAs including
miR-99a, miR-100, miR-125b, miR-192, and miR-429 have been reported in pancreatic
CSCs [15]. Additionally, we demonstrated that miR-200b was down-regulated in FoxM1
over-expressing or Notch-1 over-expressing PC cell lines, which have undergone EMT
consistent with CSCs phenotype [16,17]. Taken together, miRNAs have been shown to play
an important role in pancreatic CSCs self-renewal.
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tInterestingly, altered expression of specific miRNAs has been found to be involved in drug-
resistant PC cells. Previous reports from our laboratory have shown that the expression of
miR-200 family and let-7 family was significantly down-regulated in gemcitabine-resistant
cells [10]. Moreover, we have demonstrated that re-expression of miR-200 family resulted
in increased cell sensitivity to gemcitabine [10]. In support of the role of miRNAs in drug
resistance, Park et al. [18] found that anti-sense inhibition of miR-21 or miR-221 sensitizes
the effects of gemcitabine in pancreatic adenocarcinoma. In agreement with this concept,
Giovannetti et al. [19] showed that over-expression of miR-21 significantly suppressed anti-
tumor activity by gemcitabine, suggesting that targeting miR-21 could be beneficial for
overcoming gemcitabine chemo-resistance. Taken together, these data suggest that the
regulation of miRNA could make drug-resistant cells to become drug-sensitive, and such
strategy could be helpful to overcome drug resistance in PC.
As deregulation of miRNAs such as miRNAs over-expression or down-regulation plays
critical roles in PC progression, targeting the mature miRNAs or their precursors by
synthetic anti-sense olignucleotides or up-regulation of miRNAs ectopically could be a
novel strategy for PC therapy. Indeed, one study revealed that transfection of the synthetic
Gli-1-miRNA-3548 inhibited cell division and induced late apoptosis in PC cells [20].
Inhibition of miR-21 using anti-sense olignucleotides suppressed proliferation, and
increased apoptosis in PC cell lines [18]. Similarly, over-expressions of miR-34 by using
miR-34 mimics or infection with lentiviral miR-34 construct decreased cell clonogenicity
and invasion as well as induced apoptosis [13]. Interestingly, several drugs have been
reported to regulate the expression of miRNAs. For example, we found that metformin
increased the expression of several miRNAs such as let-7a, let-7b, miR-26a, miR-101,
miR-200b, and miR-200c [21].
Recently, accumulated evidence revealed that chemopreventive agents commonly known as
natural compounds could target miRNAs to regulate the key cellular protein expression. Due
to lack of toxicity, natural compounds have attracted more attention as chemopreventive
agents to target miRNAs in recent years. We have shown that isoflavoned 3,3’-
diindolylmethane (DIM) increased the expression of miR-200 family in PC cells [10]. More
importantly, isoflavone or DIM treatment enhanced the sensitivity of gemcitabine-resistant
cells to gemcitabine, which was in part mediated through up-regulation of miR-200 in PC
cells [10]. Similarly, we demonstrated that curcumin increased PC cell sensitivity to
gemcitabine through increased miR-200 and decreased miR-21 [22]. Moreover, we found
that CDF, a novel synthetic analog of curcumin, inhibited the sphere-forming ability of PC
cells and suppressed tumor growth, which was associated with decreased miR-21 expression
and increased miR-200 expression [22]. Furthermore, we demonstrated that CDF inhibited
PC cell survival, migration, invasion and CSC function in part via up-regulation of multiple
tumor suppressive miRNAs including let-7 family, miR-26a, miR-101, miR-146a, and
miR-200b [21]. Additionally, we found that genistein inhibited cell growth was partly
mediated through up-regulation of miR-200b in Notch-1 or FoxM1 over-expressing PC cells
[16,17]. These results provide experimental evidence showing that natural compounds could
function as miRNA regulators, suggesting that the regulation of miRNAs by nutraceuticals
could be a novel strategy for achieving better treatment outcome of patients diagnosed with
PC.
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tCollectively, these studies clearly suggest the important roles of miRNAs in cell growth,
apoptosis, invasion, metastasis, EMT, stem cells self-renewal, and drug resistance.
Therefore, identification of deregulated miRNAs in PC could be useful for tumor diagnosis,
disease prognosis, and for assessing therapeutic outcome. Targeting miRNAs, specifically
by natural compounds could open newer avenues for the prevention of tumor progression or
treatment of PC. However, further in-depth investigation is required to fully understand how
miRNAs are involved in the development and progression of PC, and finding which agents
including natural compounds and how they could regulate the expression of distinct
miRNAs. The answers will help us to design novel treatment strategies for the cure of PC
patients.
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